MX347828B - Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento. - Google Patents

Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento.

Info

Publication number
MX347828B
MX347828B MX2014001252A MX2014001252A MX347828B MX 347828 B MX347828 B MX 347828B MX 2014001252 A MX2014001252 A MX 2014001252A MX 2014001252 A MX2014001252 A MX 2014001252A MX 347828 B MX347828 B MX 347828B
Authority
MX
Mexico
Prior art keywords
compounds
aza
phenyl
metanonas
hex
Prior art date
Application number
MX2014001252A
Other languages
English (en)
Other versions
MX2014001252A (es
Inventor
Rosenbrock Holger
Giovannini Riccardo
Mazzaferro Rocco
Ferrara Marco
Bertani Barbara
Lingard Iain
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2014001252A publication Critical patent/MX2014001252A/es
Publication of MX347828B publication Critical patent/MX347828B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Las presentes invenciones se refiere a fenil-3-aza-biciclo[3, 1 ,0]hex3-il-metanonas sustituidas de la fórmula general (I) (ver Fórmula) en donde R1, R2, R3, R4, R5 y R6 son como se describen en la presente o sus sales, con preferencia, sus sales farmacéuticamente aceptables. La invención también se refiere a la preparación de dichos compuestos, composiciones farmacéuticas que comprenden un compuesto de acuerdo con la fórmula general (I) y el uso de dichos compuestos para el tratamiento de diversas condiciones tales como condiciones referidas a síntomas positivos y negativos de esquizofrenia, así como las alteraciones cognitivas asociadas con esquizofrenia, enfermedad de Alzheimer y otros trastornos neurológicos y psiquiátricos. Los compuestos de la invención muestran propiedades inhibidoras del transportador de glicina 1 (GIyT1).
MX2014001252A 2011-08-03 2012-08-02 Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento. MX347828B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11176468 2011-08-03
PCT/EP2012/065140 WO2013017657A1 (en) 2011-08-03 2012-08-02 Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament

Publications (2)

Publication Number Publication Date
MX2014001252A MX2014001252A (es) 2014-05-13
MX347828B true MX347828B (es) 2017-05-15

Family

ID=46598566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001252A MX347828B (es) 2011-08-03 2012-08-02 Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento.

Country Status (37)

Country Link
US (1) US9012489B2 (es)
EP (1) EP2739615B1 (es)
JP (1) JP5850589B2 (es)
KR (1) KR101944686B1 (es)
CN (2) CN105837562B (es)
AP (1) AP2014007399A0 (es)
AR (1) AR087436A1 (es)
AU (1) AU2012292036C1 (es)
BR (1) BR112014001642B1 (es)
CA (1) CA2843805C (es)
CL (1) CL2014000246A1 (es)
CO (1) CO6870037A2 (es)
CY (1) CY1119326T1 (es)
DK (1) DK2739615T3 (es)
EA (1) EA024933B1 (es)
EC (1) ECSP14013221A (es)
ES (1) ES2623006T3 (es)
GE (1) GEP20166483B (es)
HR (1) HRP20170695T1 (es)
HU (1) HUE033134T2 (es)
IL (1) IL229962A (es)
LT (1) LT2739615T (es)
MA (1) MA35286B1 (es)
ME (1) ME02672B (es)
MX (1) MX347828B (es)
MY (1) MY167396A (es)
PE (1) PE20141352A1 (es)
PH (1) PH12014500276A1 (es)
PL (1) PL2739615T3 (es)
PT (1) PT2739615T (es)
RS (1) RS55927B1 (es)
SI (1) SI2739615T1 (es)
TN (1) TN2014000044A1 (es)
TW (1) TWI543974B (es)
UA (1) UA114405C2 (es)
UY (1) UY34239A (es)
WO (1) WO2013017657A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3151669T3 (pl) 2014-06-06 2021-04-19 Basf Se Zastosowanie podstawionych oksadiazoli do zwalczania fitopatogennych grzybów
AR106679A1 (es) 2015-11-13 2018-02-07 Basf Se Oxadiazoles sustituidos para combatir hongos fitopatógenos
EP3373735A1 (en) 2015-11-13 2018-09-19 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
JP2018537457A (ja) 2015-11-19 2018-12-20 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 植物病原菌を駆除するための置換オキサジアゾール
RU2018138748A (ru) 2016-04-11 2020-05-12 Басф Се Замещенные оксадиазолы для борьбы с фитопатогенными грибами
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
EA202192925A1 (ru) * 2019-05-01 2022-03-23 Бёрингер Ингельхайм Интернациональ Гмбх Твердые формы ингибитора glyt1
US11813257B2 (en) 2020-01-09 2023-11-14 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
MX2023001818A (es) 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking
WO2023097276A1 (en) * 2021-11-24 2023-06-01 Maplight Therapeutics, Inc. Methods of treating neurological disorders
CN114957087A (zh) * 2022-04-13 2022-08-30 湖南复瑞生物医药技术有限责任公司 一种帕罗韦德中间体制备方法
TW202348602A (zh) * 2022-06-10 2023-12-16 大陸商成都百裕製藥股份有限公司 吡咯烷衍生物、藥物组合物及其製藥用途
CN119768399A (zh) * 2022-08-24 2025-04-04 勃林格殷格翰国际有限公司 GlyT-1抑制剂的可规模化制备方法
KR20260030069A (ko) * 2023-05-25 2026-03-05 맵라이트 세라퓨틱스, 인크. 신경학적 장애를 치료하기 위한 조성물
WO2025140479A1 (zh) * 2023-12-29 2025-07-03 苏州科睿思制药有限公司 Iclepertin的晶型及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009059B1 (ru) 2003-04-10 2007-10-26 Рэнбакси Лабораториз Лимитед Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
RS20060190A (sr) 2003-10-14 2008-08-07 Pfizer Products Inc., Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
DE102004035280A1 (de) 2004-07-21 2006-03-16 Robert Bosch Gmbh Kraftstoffinjektor mit direkter mehrstufiger Einspritzventilgliedansteuerung
MX2007008190A (es) * 2005-01-06 2007-08-07 Hoffmann La Roche Fenil metanonas sustituidas con sulfanilo como inhibidores del transportador de glicina 1 (glyt-1) para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
BRPI0519794A2 (pt) * 2005-01-07 2009-03-17 Hoffmann La Roche derivados de [4-(heteroaril)piperazin-1-il]-(fenil 2,5-substituìdo)metanona como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distúrbios neurológicos e neuropsiquiátricos
DE602006010665D1 (en) * 2005-02-07 2010-01-07 Hoffmann La Roche Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1
JP4937347B2 (ja) * 2006-06-22 2012-05-23 エフ.ホフマン−ラ ロシュ アーゲー 置換フェニルメタノン誘導体
AU2007265467C1 (en) 2006-06-28 2013-11-07 Amgen Inc. Glycine transporter-1 inhibitors
TW200833328A (en) * 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EP2381941A4 (en) * 2008-12-29 2012-08-01 Univ Vanderbilt 3.1.0 BICYCLIC GLYTI INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
SG173116A1 (en) 2009-01-27 2011-08-29 Hoffmann La Roche Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors

Also Published As

Publication number Publication date
NZ619258A (en) 2015-12-24
US20130197011A1 (en) 2013-08-01
AR087436A1 (es) 2014-03-26
KR20140051922A (ko) 2014-05-02
EA201400183A1 (ru) 2014-06-30
AU2012292036B2 (en) 2016-10-06
CY1119326T1 (el) 2018-02-14
RS55927B1 (sr) 2017-09-29
TWI543974B (zh) 2016-08-01
MA35286B1 (fr) 2014-07-03
CN103797005B (zh) 2016-05-11
PH12014500276A1 (en) 2017-02-01
CN103797005A (zh) 2014-05-14
EP2739615B1 (en) 2017-03-15
US9012489B2 (en) 2015-04-21
LT2739615T (lt) 2017-04-10
MY167396A (en) 2018-08-16
UY34239A (es) 2013-02-28
KR101944686B1 (ko) 2019-02-01
TN2014000044A1 (en) 2015-07-01
BR112014001642B1 (pt) 2022-03-22
ECSP14013221A (es) 2014-03-31
ME02672B (me) 2017-06-20
EA024933B1 (ru) 2016-11-30
CN105837562A (zh) 2016-08-10
TW201321364A (zh) 2013-06-01
EP2739615A1 (en) 2014-06-11
ES2623006T3 (es) 2017-07-10
AU2012292036A1 (en) 2014-01-16
JP2014524414A (ja) 2014-09-22
IL229962A (en) 2016-09-29
AU2012292036C1 (en) 2017-03-23
PE20141352A1 (es) 2014-10-12
CA2843805A1 (en) 2013-02-07
HRP20170695T1 (hr) 2017-07-28
PL2739615T3 (pl) 2017-08-31
HUE033134T2 (en) 2017-11-28
CL2014000246A1 (es) 2014-08-08
CN105837562B (zh) 2020-01-17
PT2739615T (pt) 2017-06-09
BR112014001642A2 (pt) 2017-02-14
DK2739615T3 (en) 2017-05-08
JP5850589B2 (ja) 2016-02-03
GEP20166483B (en) 2016-05-25
UA114405C2 (uk) 2017-06-12
CO6870037A2 (es) 2014-02-20
HK1193100A1 (zh) 2014-09-12
MX2014001252A (es) 2014-05-13
SI2739615T1 (sl) 2017-07-31
WO2013017657A1 (en) 2013-02-07
CA2843805C (en) 2021-03-23
AP2014007399A0 (en) 2014-01-31

Similar Documents

Publication Publication Date Title
MX347828B (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento.
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
DOP2013000194A (es) Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicos
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
ECSP12011857A (es) Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
UY32574A (es) Antagonistas del receptor cxcr3
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
UY32391A (es) Compuestos amino-heterocíclicos
AR085219A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
UY35012A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
MX347706B (es) Derivados de triazol y su uso para trastornos neurologicos.
CO7280468A2 (es) Antagonistas del receptor de 5-ht3
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
DOP2015000214A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CR20120131A (es) Uso de derivados del indol como activadores de nurr-1, para su aplicación como medicamento en el tratamiento de la enfermedad de parkinson
CO6640307A2 (es) Derivados de flufenoxina para el tratamiento y la prevención de patologías amiloides
CU20100124A7 (es) 3-hidroxipiridinas sustituidas y composiciones farmacéuticas de las mismas
CU20140021A7 (es) Derivados de 2- amino-4- (piridin-2-il)-5,6- dihidro-4h-1,3- oxacina y su uso como inhibidores de bace -1 y/o bace-2

Legal Events

Date Code Title Description
FG Grant or registration